Market Overview

Deutsche Bank Reiterates Ratings, Price Targets On Several Pharma Firms

In a note out today, Deutsche Bank reiterated a buy rating and $97 price target on Botox maker Allergan (NYSE: AGN), implying substantial upside from where the shares currently trade.

The bank also reiterated a hold and $33 price target on Forest Labs (NYSE: FRX). Deutsche Bank also reiterated buy ratings on Teva (Nasdaq: TEVA) and Medicis Pharmaceutical (NYSE: MRX) with price targets of $46 and $44, respectively.

Posted-In: Analyst Color News Price Target Reiteration Intraday Update Markets Analyst Ratings Trading Ideas

 

Related Articles (AGN + FRX)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters